Humanin was discovered in 2001 by a Japanese research group studying the brains of Alzheimer's disease patients (Hashimoto et al., Proceedings of the National Academy of Sciences, 2001). They found that surviving neurons in affected brain regions expressed a previously unknown peptide encoded by the 16S ribosomal RNA gene of mitochondrial DNA. This peptide, named humanin, protected neuronal cells against amyloid beta toxicity in vitro.
Since its discovery, humanin has been recognised as the founding member of a class called mitochondrial-derived peptides (MDPs), which also includes MOTS-c and SHMOTs (small humanin-like peptides). These peptides are encoded by short open reading frames within mitochondrial DNA and function as systemic signalling molecules.
Mechanism of Action
Humanin exerts its effects through multiple pathways:
- IGFBP-3 interaction: Humanin binds to insulin-like growth factor binding protein-3 (IGFBP-3), blocking IGFBP-3-induced apoptosis. This interaction influences cell survival in both neural and peripheral tissues (Ikonen et al., 2003).
- STAT3 signalling: Humanin activates the STAT3 pathway through the CNTFR/WSX-1/gp130 receptor complex, promoting cell survival and reducing inflammation (Hashimoto et al., 2009).
- BAX inhibition: Humanin directly interacts with the pro-apoptotic protein BAX, preventing it from forming pores in the mitochondrial outer membrane. This blocks the intrinsic apoptosis pathway.
- AMPK activation: Humanin has been shown to activate AMP-activated protein kinase (AMPK) in peripheral tissues, improving glucose uptake and fatty acid oxidation (Lee et al., 2015).
Humanin and Ageing
Circulating humanin levels decline significantly with age. A study by Muzumdar et al. (2009) in Aging Cell found that plasma humanin levels in elderly humans (65-90 years) were approximately 50% lower than in younger adults (20-40 years). This decline correlates with:
- Reduced mitochondrial function
- Increased susceptibility to oxidative stress
- Higher rates of neurodegenerative disease
- Impaired insulin sensitivity
Interestingly, children of centenarians have been found to have higher circulating humanin levels than age-matched controls (Yen et al., 2020), suggesting a genetic component to humanin production that may contribute to exceptional longevity.
Neuroprotection
Humanin's neuroprotective effects are the most extensively studied. In Alzheimer's disease models, humanin and its analogues have been shown to:
- Protect against amyloid beta-induced neurotoxicity (Hashimoto et al., 2001)
- Reduce tau phosphorylation in vivo (Tajima et al., 2005)
- Improve cognitive performance in transgenic AD mouse models
- Reduce neuronal apoptosis following ischaemic stroke models
These findings have not yet been replicated in human clinical trials.
Metabolic Effects
Beyond neuroprotection, humanin influences metabolic health:
- Insulin sensitivity: Exogenous humanin administration improved insulin sensitivity in high-fat-diet mice (Lee et al., Cell Metabolism, 2015)
- Visceral fat reduction: Humanin-treated mice showed reduced adiposity without changes in food intake
- Cardiac protection: Humanin protected cardiomyocytes against oxidative stress-induced apoptosis in ischaemia-reperfusion models (Thummasorn et al., 2016)
Humanin vs MOTS-c
| Feature | Humanin | MOTS-c |
|---|---|---|
| Origin | 16S rRNA gene (mtDNA) | 12S rRNA gene (mtDNA) |
| Size | 24 amino acids | 16 amino acids |
| Primary effects | Anti-apoptotic, neuroprotective | Exercise mimetic, AMPK activator |
| Decline with age | Yes | Yes |
| Clinical trials | None completed | None completed |
Both peptides represent the emerging field of "mitochondrial medicine" and are central to the thesis that mitochondrial dysfunction is a root driver of ageing. For more on MOTS-c, see our dedicated guide.
Current Research Status
As of March 2026, humanin research remains predominantly preclinical. No commercially available humanin supplements exist. The peptide's primary value currently lies as a biomarker for mitochondrial health and longevity potential, and as a therapeutic target for neurodegenerative disease.
Synthetic humanin analogues with improved stability and potency (such as HNG, HNGF6A, and S14G-humanin) are used in research settings. These analogues have 1000x greater potency than native humanin in some assays.
Key References
- Hashimoto, Y. et al. (2001). "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." PNAS, 98(11), 6336-6341.
- Lee, C. et al. (2015). "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3), 443-454.
- Muzumdar, R.H. et al. (2009). "Humanin: a novel central regulator of peripheral insulin action." PLoS ONE, 4(7), e6334.
- Yen, K. et al. (2020). "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging, 12(12), 11185-11199.